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Background: Production of human monoclonal antibodies that exhibit broadly neutralizing activity is needed for
preventing HIV-1 infection, however only a few such antibodies have been generated till date. Isolation of
antibodies by the hybridoma technology is a cumbersome process with fewer yields. Further, the loss of unstable
or slowly growing clones which may have unique binding specificities often occurs during cloning and
propagation and the strongly positive clones are often lost. This has been avoided by the process described in this
paper, wherein, by combining the strategy of EBV transformation and recombinant DNA technology, we
constructed human single chain variable fragments (scFvs) against the third variable region (V3) of the clade C
HIV-1 envelope.
Results: An antigen specific phage library of 7000 clones was constructed from the enriched V3- positive antibody
secreting EBV transformed cells. By ligation of the digested scFv DNA into phagemid vector and bio panning
against the HIV-1 consensus C and B V3 peptides followed by random selection of 40 clones, we identified 15
clones that showed V3 reactivity in phage ELISA. DNA fingerprinting analysis and sequencing showed that 13 out
of the 15 clones were distinct. Expression of the positive clones was tested by SDS-PAGE and Western blot. All the
13 anti-V3 scFvs showed cross-reactivity against both the clade C and B V3 peptides and did not show any
reactivity against other unrelated peptides in ELISA. Preliminary neutralization assays indicated varying degrees of
neutralization of clade C and B viruses. EBV transformation, followed by antigen selection of lines to identify specific
binders, enabled the selection of phage from un-cloned lines for scFv generation, thus avoiding the problems of
hybridoma technology. Moreover, as the clones were pretested for antigen binding, a comparatively small library
sufficed for the selection of a considerable number of unique antigen binding phage. After selection, the phage
clones were propagated in a clonal manner.
Conclusions: This strategy can be efficiently used and is cost effective for the generation of diverse recombinant
antibodies. This is the first study to generate anti-V3 scFvs against HIV-1 Clade C.
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There is a rapid increase in the number of human
immunodeficiency virus (HIV-1) infected individuals
worldwide and so far we have met with little success in
slowing down or preventing the progression of this
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reproduction in any medium, provided the orantibodies as effective reagents for passive immunotherapy
to slow or to halt the disease progression in HIV-1
infected individuals and for immunogen design for vaccin-
ation to prevent the infection, the generation of large
numbers of human HIV-1 specific monoclonal antibodies
is desirable. Although a few human broadly neutralizing
antibodies (bNAbs) to HIV-1 exist [1-10], these antibodies
have limited reactivity against non-clade B viruses, which
are responsible for more than 85% of the infections world-
wide [4]. Few bNAbs exist so far, that are effective against
the clade C viruses, which include the 4E10, antibodies
from the CAPRISA cohort and the recently isolatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Neutralization (ID50) of subtype-A, B and C
viruses by #254 plasma sample
Sr. No. Virus Tier Subtype ID50
1 92RW009 1 A 74
2 Q461 1 A 98
3 SF162 1 B 1296
4 JRCSF 1 B 103
5 Du156.12 2 C 206
6 ZM53M.PB12 2 C <60
7 ZM109F.PB4 2 C 104
8 JRFL 2 B <60
9 RHPA4259.7 2 B 446
10 TRO.11 2 B 162
The cross neutralizing activities of plasma antibodies from HIV-1 infected drug
naïve sample #254 against a panel of subtype-A, B, C tier 1 and 2 viruses indicated
on left. The numerical values on the extreme right of table represent the mean
50% neutralization titers (ID50) defined as the reciprocal dilution of plasma which
neutralized 50% of viral infection in the assay. For clarity, this information is coded;
ID50> 1000 (Bold), ID50= 100-l000 (Bold Italic), ID50= 61–100 (Italic) and ID50<60,
where 50% neutralization was not reached. Each experiment was performed at
least two independent times and in duplicates.
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order to evaluate their utility in combating HIV-1 infection,
and to tackle the problems posed by the extensive diversity
of HIV-1, it is essential to generate a large panel of human
anti-HIV-1 antibodies of different specificities. Further, it
may be necessary to evaluate several antibodies to find rare
but highly effective molecules.
The methods used for the generation of human
monoclonal antibodies include the hybridoma technology,
recombinant technology by phage display and the recently
employed techniques such as single B cell sorting followed
by amplification of heavy and light chain genes [8,13,14].
Generation of antibodies by the conventional hybridoma
technology is not adequate enough to meet the challenge
of assessing large numbers of human monoclonal anti-
bodies from HIV-1 infected individuals at various stages
of their clinical course. Our approach to the problem has
been to combine the antigen specific pre-selection of
EBV transformed B cells with the construction of a phage
library.
Phage display is a scalable method for antibody produc-
tion against a wide variety of antigens [15-17]. Investigators
are using this technology for the production of antibodies
with the desired isotype specificities and affinity for
research, clinical and industrial applications. Antibody gene
variable regions are amplified and expressed on the surface
of filamentous bacteriophage as a fusion protein [14] and a
number of antibodies can be produced from a single library
and can be expressed and produced in a prokaryotic
system. The major drawback in this technology is the
requirement for the construction of large sized phage
libraries (109-1010) with an optimum diversity because the
diversity of these libraries primarily determines the
successful isolation of the desired antibodies. Construction
of such large libraries requires a number of ligation and
electroporation reactions. Screening of positive clones from
these libraries generally require at least three to seven
rounds of biopanning to select specifically binding clones
[18,19]. It is also difficult to maintain such large sized
libraries. Keeping all these factors in mind we have
described here a simple and efficient method for the
production of human monoclonal antibodies using a
combinational approach of EBV transformation, antigen
preselection and phage display technology. A similar
approach was previously used by Kempf et al. to isolate
Fabs to the gp120 of HIV-1 [20]. Here, we adopted a
modified strategy and isolated for the first time, human
anti-V3 scFvs from the EBV transformed lymphocytes of a
clade C HIV-1 infected patient. This method can be used
to produce large panels of viral specific phage libraries in
less time and in a cost effective manner.
A limited number of monoclonal antibodies are
generated against the HIV-1 Clade C which is the most
predominant subtype worldwide and in India [21]. The V3region of HIV-1 gp120 is an important target to induce
neutralizing antibodies against different strains of HIV-1. It
exhibits a high degree of sequence variability in the most
structurally conserved region of the HIV-1 envelope
[22,23] and it interacts with the co-receptors CCR5 and
CXCR4 [7,24,25]. In this study, we constructed a scFv
library from the EBV transformed B cells of an HIV-1
infected patient #254, reactive to the third variable (V3)
region of gp120 of HIV-1 clade C. The plasma sample of
this patient was previously tested and found to exhibit
cross neutralizing activity against a standard panel of pseu-
doviruses of different clades (Table 1) and also had cross
reactive binding antibodies to clade C and B V3 peptides
[26,27]. The modified strategy used here employing EBV
transformation; antigen preselection followed by phage
library construction enabled the successful selection of
human monoclonal recombinant scFvs specific to the V3
antigen of HIV-1. Construction of human scFv phage
library from these antigen preselected B cells led to an
efficient and cost effective approach for the production of
anti-V3 scFvs.
Results
Viral neutralization and cross reactive binding activity of
the patient plasma #254
The plasma antibodies of the HIV-1 infected patient
#254 displayed neutralizing activity against 8 out of 10
HIV-1 viruses from subtype-A, B and C (Table 1). The
plasma sample also showed a cross subtype-B and C























Figure 1 Level of Anti V3 antibodies in patient plasma (#254). 50% reciprocal binding titer of the plasma of the patient (#254) against
consensus clade C and B V3 peptides. The results depict the average OD values of three independent experiments.
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A total of 4.8 million PBMCs were isolated from the
HIV-infected patient (# 254) and EBV transformed in 48
wells of a 96 well culture plate (Figure 2). After 2 weeks,
the cultures were screened (first screening) for the presence
of anti-V3 antibodies and 7/48 wells showed high V3
binding reactivity with OD> 2. Cells from these 7 V3
positive wells were expanded to a 24 well plate and after a
second screening, cells from 5 out of 7 wells showing V3
binding with OD > 0.6 were expanded in a six-well plate,
pooled and finally transferred to a T- 25 flask. In the
3rd (final) screening of the cells in the flask, the cells
showed high reactivity to V3 (OD > 1) (Table 2). These V3
positive (enriched) cells were processed for recombinant
anti-V3 scFv generation.
Phage library construction
Total RNA from the V3 enriched antibody producing B
cells of the patient #254 was isolated. A total of 200ng of
RNA was reverse transcribed to cDNA. Use of random
hexamer and oligo dT in the cDNA synthesis process
was shown to be more effective than either of them
alone or the 30 primers [15,20]. It also enhanced the
chances of amplification of the antibody genes even
when the amount of RNA is low [15]. A total of 54
combinations were used to amplify the heavy and light
chains (24 for VH and 30 for VL). Among the 24 combi-
nations of heavy chains, 18 were successfully amplified.
The heavy chains VH1, VH4, VH5 and VH6 were prefer-
entially more expressed while VH2 and VH3 were very
less expressed (Figure 3A). All the 30 kappa light chain
combinations were successfully amplified and expressed
almost at the same level, except for VLK2, which were
relatively less expressed (Figure 3B). A heavy chain and
light chain pool was made by mixing equal concentration
of each combination (50ng) irrespective of their expressionlevel, so that each combination of the heavy chain has an
equal probability to combine with the light chain and vice
versa and to avoid the predominant expression of one
antibody subclass and finally to have new combinations of
antibodies for a particular antigen that are naturally not
elicited during the natural course of infection. A final pull
through PCR was performed using the forward and
reverse primers. These scFvs were then ligated into the
pCANTAB-5E vector that contains the Sfi1 and NotI sites
(Figure 3). The ligated product was transformed into TG1
using calcium chloride mediated transformation. The
incubation time after the heat shock treatment during
transformation was maintained for a maximum of 40 min
to avoid repetition of similar types of clones in the library.
We obtained 200–300 transformed colonies per plate. A
total of 7000 colonies were obtained with 400ng of digested
scFv DNA that were ligated into 1 μg of phagemid vector.
The ligated DNA was transformed into E.coli TG1.Diversity of the phage antibody library
To check the diversity of antibodies in the library, we
randomly selected 10 clones from the unselected library.
Amplification of these 10 scFvs by PCR, followed by
digestion with BstN1 and comparing their DNA finger-
print patterns showed that 9/10 clones were distinct
from each other. Clone 3 and clone 6 showed identical
DNA fingerprinting patterns (Figure 4).
We further confirmed the diversity of the antibody
fragments by DNA sequence analysis of 29 randomly
selected scFv clones from the unselected library which
showed high diversity of clones i.e. 73% (21/29) in the
library. The heavy chain (VH) sequences showed a
limited diversity, IGVH4 (13/29) and IGVH5 (15/29)
were the most preferentially represented VH sequences
that combined with all the representatives of IGHD
  scFv construction
Cloning into pCANTAB-5E vector 
Total RNA 
Pooled and transferred to culture flasks 
Amplification of VH and VL genes
Positive wells expanded
96 well stage 



























Figure 2 Schematic overview of the strategy used for construction of antigen specific phage library. The peripheral blood mononuclear
cells (PBMCs) were isolated from an antiretroviral drug naïve patient (#254) whose plasma exhibited neutralizing activity against a panel of viruses
and also displayed cross clade reactive anti-V3 antibody binding potential. PBMCs were subjected to EBV transformation in 96 well culture plate,
wells showing high level of anti-V3 antibodies were selected and expanded to 24 well stage and then to six well stage . The wells showing high
titre of anti-V3 Abs were pooled together and cultured in T25 flask. Total RNA was isolated from these antigen specific enriched B cells and cDNA
was synthesised. Heavy and light chains were amplified and scFvs were constructed and cloned into a pCANTAB-5E phagemid vector. scFv
phage library of 7000 clones was constructed.
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was also limited with IGKV1, IGKV2 and IGKV3 being
most represented, except for one occurrence of IGKV7
(Table 3).Selection of scFvs against the V3 region of HIV-1
As the size of the library was very small, one round of
biopanning was done against the V3 C and V3 B peptides.
Forty clones were randomly selected and checked for
Table 2 Screening of EBV transformed PBMCs isolated
from a drug naïve HIV-1 infected patient (# 254) for V3
reactivity
1Total number of PBMCs isolated (millions) from
HIV-1 infected patient # 254
4.8
2Number of cells plated per well 100000
3Total number of wells plated with the cells and
EBV transformed in 96 well culture plate
48
4Number of wells successfully EBV transformed 48
5Number of wells secreting anti-V3 Abs (OD>2)
in 96 well stage(first screening)
7
6Number of wells secreting anti-V3 Abs (OD>0.6)
in 24 well stage(second screening)
5
7OD at flask stage(Final screening) (OD>1.0)
1 PBMCs were isolated from a HIV positive drug naïve patient sample (# 254).
A total of 4.8 million PBMCs were isolated.
2 Number of cells plated per well was 100000.
3 Forty eight wells were subjected to EBV transformation.
4 All the 48 wells were successfully transformed (transformation efficiency
100%).
5 7/48(approx 14.6%) wells showed positive binding (OD>2) with V3 peptide
and expanded to 24 well stage.
6 5/7 (approx 71%) wells showed positive binding (OD>0.6) with V3 peptide
and pooled down and grown in T-25 flask.
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Figure 3 Amplification of VH and VL genes. A. Agarose gel
electrophoresis (1%) of PCR amplified products of heavy chain (VH)
genes using all combinations of the 24 primers. Lane B, PCR blank
(negative control); Lane M, DNA marker (100 bp ladder); Lanes 1–6 is
with VH1-6 with reverse primers (R1, R2, R3 and R4). Samples that
were loaded in duplicates are indicated as numbers 2, 2 and 3, 3 so
on. B. Agarose gel electrophoresis (1%) of PCR amplified products of
light chain (VL) genes. Lane B, PCR blank negative control; Lane M,
DNA marker (100 bp ladder); Lane 1–6 is with VKL1-6 with reverse
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ELISA with both the peptides (Figure 5). Four clones were
randomly selected for ELISA with purified phage. The
binding specificity of these anti-V3 scFvs was checked
with phage from the 24 well plate and PEG precipitated
purified phage. The 24 well ELISA and pure phage ELISA
binding assays showed similar results. Three clones
exhibited almost similar binding in both the formats of
ELISA while one clone had lower binding reactivity in
pure phage ELISA although it was not completely lost
(data not shown). DNA fingerprinting analysis using
BstN1 followed by sequencing revealed that 13/15 clones
were distinct (Table 4). All the distinct 13 anti -V3 scFvs
that were finally selected, showed cross-reactivity against
both the V3 peptides and did not show any reactivity
against other unrelated peptides. One round of biopanning
was found to be sufficient to get V3 positive scFv clones
with diversity.primers. C. Pull through PCR for scFv construction, Agarose gel
electrophoresis (1%) of PCR amplified products of scFvs constructed
by pull through PCR. Lane M, DNA ladder (100 bp); Lanes 1 & 2 are
amplified scFv DNA products.Soluble scFv production
The antigen binding clones showing positivity/binding in
the phage ELISA were further processed for soluble scFv
expression by induction with 1mM IPTG [28]. After
induction, the periplasmic lysate, inclusion bodies, culture
supernatant and whole cell extract were prepared and
analysed for scFv expression on a 12% reducing SDS-
PAGE. The scFv fusion protein was found to be expressed
in the cell lysate, culture supernatant, periplasmic extract,
with highest expression in the inclusion bodies. scFvexpression was also observed in the uninduced culture
(Figure 6).Purification of E-tagged scFv and Western blot analysis
The scFvs were expressed in E. coli HB2151 cells by
inducing for 6 to 8 h with 1 mM IPTG at 24°C. The
1     2    3     4    5    6    7     8    9    10    M 
Figure 4 DNA fingerprinting analysis of scFv clones. Ten scFv
gene fragments were amplified by PCR and digested with BstN1 at
60°C for 3 hours. Restriction pattern was analysed on 2% agarose
gel. Arrows indicate that clones 3 and 6 exhibit identical DNA
fingerprinting pattern. Lane M, DNA ladder (100 bp).
































Identical sequences of clones 15 and 16, 18 and 19, 22, 23 and 24 are shown in ital
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extract and the purified product was analysed by SDS-
PAGE. The scFv protein of 32kDa was expressed in
different elute fractions E1 to E5 (Figure 7C) and protein
samples were concentrated using ultrafiltration columns
(Ambion) over a 10kDa cut off.
Expression of the scFv fusion protein (32 kD) in the
periplasmic extract was confirmed by Western blotting.
The cell lysate of HB2151 was used as a negative control
(Figure 7D).
Validation of antigen binding of the scFv clones
The functional activity of the newly generated clones











































































































Figure 5 Phage ELISA binding specificity. Selection of clones exhibiting binding to the V3 peptides of clade C and clade B HIV-1. ELISA wells
were coated with the V3C and V3B peptide. MPER peptide, ID loop peptide, BSA and a peptide pool of unrelated viruses were used as negative
controls. The experiment was done in duplicates and repeated at least twice and the mean OD values are shown. Clones showing O.D three
times the negative control was considered as positive.
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showed specific binding to the V3 peptides (Figure 8). In
addition, these scFvs did not bind to other unrelated
peptides like MPER and ID loop of HIV, peptide pool













This table shows the gene usage of the ten anti-V3 scFvs. Nine out of the ten seque
shown in italic.Neutralization potential of anti-V3 scFvs
The purified scFvs were tested for the viral neutra-
lization potential against a panel of pseudoviruses from
clades A, B and C HIV-1 viruses (Table 5). Clone 3E6B












nces are distinct. Clones 3C3C and 3E7B show similar gene usage which are
(Bacterial crude extract)




Figure 6 Localization of scFv antibody in different fractions.
Lane M, protein molecular weight marker ; lane L, cell lysate fraction;
lane S, culture supernatant; lane P1 and P2 are, periplasmic fraction
(20 μl and 10 μl respectively loaded); lane I, inclusion body
(insoluble) fraction. Lane –Ve control, cell lysate of phagemid vector
without scFv was used.
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neutralize 1 clade C virus.
Discussion
We have demonstrated in this study a strategy that
successfully yielded recombinant human scFvs against
the V3 region of HIV-1 using a pool of antigen selected
EBV transformed B lymphocytes and phage display tech-
nology. The use of preselected B cells producing anti- V3
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Figure 7 Analysis of scFv clones by agarose gel electrophoresis (1%)
randomly selected clones from library before panning. B. Agarose gel analy
from library before panning. Lane M, 100 bp marker; Lane M1 1kb ladder; L
%) of purified scFv Lane M, protein marker; Lane E1 to E5, different eluted
to E5 lanes. D. Western blot analysis of purified scFv, pCANTAB-5E vector p
molecular weight marker.be an efficient strategy for the isolation of V3 specific
clones. Moreover, this approach has prevented any loss of
unstable or slowly growing clones which may have useful
and unique binding specificities (that often occurs during
cloning and propagation).
Stringency during the initial stages helps in elimination
of most of the false positive clones. Beginning with the
96 well stage and up to the final screening of the cells in
the T25 flask, we selected only those wells with high V3
binding reactivity for further expansion and finally for
the phage library construction. By this approach, we
obtained a phage library with an adequate number of V3
binding clones. Amplification of the heavy chain gene
showed that the VH1, VH4, VH5 and VH6 were prefer-
entially more expressed than the VH2 and VH3 and
corroborated with the previous reports [29] that anti-V3
antibodies more preferentially exhibit the above gene
usages. It is well established that in HIV-1 infection,
VH3 genes are less preferentially used [30,31]. From the
sequencing data, we observed that twenty nine randomly
selected clones from the EBV transformed cells library
exhibited the VH4 and VH5 gene usage suggesting that
our library may be biased towards antigen specificity. In
healthy individuals, VH3 genes are most frequently used
and VH5 is used only by a low percentage of antibodies
(http:imgt.cines.fr). The light chain did not show any
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and purification of scFvs. A. Agarose gel analysis of colony PCR of 10
sis of SfiI and NotI digested plasmid of 10 randomly selected clones
ane 1–10 are plasmid DNA from ten different clones. C. SDS- PAGE (12
fractions of purified scFv. Arrow indicates the 32kDa band of scFv in E1

























































Figure 8 Binding specificity of selected anti-V3 scFv clones. The binding of scFv antibodies was determined by ELISA against V3 peptides of
clade C and B, MPER and ID peptides of HIV, peptide pool (unrelated viruses) and BSA. The clones 3E6B and 3E7B bound specifically to V3
peptides. The experiment was performed in triplicates.
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expression of a set of heavy chain genes, to avoid
predominant expression of one subset of genes in the
phage library, we took an equal concentration of all the
heavy chain genes which in turn increased the chances
of the new combinations that are not expressed in
natural infection. Successful isolation of positive clones
with higher affinity and specificity is possible when a
library is more diverse and has less number of clones
with incomplete scFvs sequences [15,32]. If phage carrying
incomplete scFvs are more in number, they overwhelm
the library after multi-step panning thereby the presence
of the full size insert will decrease, this being a common
problem with phage libraries. Interestingly, our libraryTable 5 Neutralization potential of anti-V3 scFvs against
a panel of pseudoviruses and primary isolates
Virus Clade 3E6B 3E7B scFv (HepB) 1418
92RW A 45 >100 >150 >150
SF162 B 115 >100 >150 >150
QZ4589 B 50 >100 >150 >150
AIIMS 261 C 110 45 >150 >150
Du 422 C >150 >100 >150 >150
ZM 53 C >150 >100 >150 >150
The cross neutralizing activities of two anti-V3 scFv clones against a panel of
subtype-A, B, C viruses that are listed on the left. The numerical values in the
table represent the concentration (μg/ml) of scFvs at which 50% neutralization
titers (IC50) was reached. AIIMS 261 is the primary isolate generated in our lab
from a HIV-1 clade C infected patient. scFv (HepB) is an scFv against the
Hepatitis B surface antigen (negative control) and 1418 is human antibody to
parvovirus (negative control). Each experiment was performed at least two
independent times.exhibited 90% diversity of clones and 100% clones had
complete scFvs (Figure 7A,B), this might be because of the
optimum incubation time (30–40 min) maintained during
the transformation process that reduced the chances of
repetition of clones. In addition, the combination of the
Sfi1- NotI site containing pCANTAB-5E vector that we
used in the library construction may have reduced or
eliminated the chances of getting incomplete scFv
sequences because these restriction enzyme sites are rarely
present in the scFv DNA sequence [15,33]. Furthermore,
none of our clones had internal Sfi1- NotI sites.
Stringency in the biopanning also reduces the number
of false positive clones. Initially, phage were allowed to
bind to the plastic plate, next, to coated milk, followed
by BSA and finally onto a pool of coated unrelated antigens
in the plates. This stringency reduced the number of non-
specific phage binders and made the screening process
more convenient and specific.
Kempf et al., using a similar strategy of EBV trans-
formation, constructed a Fab library of 107 clones from
which they isolated three Fabs after one round of bio-
panning. Their scoring of positive clones however was
less, probably because they selected cells positive for
gp120 binding from the 96 well stage and also included
wells that were low binders ( OD> 0.1) [20]. We therefore
selected only those wells with high V3 binding reactivity
(OD>0.6) at all stages for the phage library construction.
This reduced the number of false positive clones and
enriched the V3 specific cells.
There are several reports on the generation of scFvs
from different sources like PBMCs [34,35], bone marrow
[36], tonsils [37], hybridomas [38,39], but none of them
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generate a scFv phage library.
Generation of phage library from EBV transformed lines
after preselection with antigen is very useful for laboratories
with limited resources because the antibody production by
traditional hybridoma technology costs ranging between
$8000 to $12000 and 80% of the costs are incurred in the
post EBV immortalization steps like fusions and cloning.
Our strategy does not require the expensive process of elec-
troporation because the cost of cuvettes and instrument
mainly limits the construction of phage libraries with such
a large size and diversity; also it eliminates the large number
of biopanning rounds followed by cumbersome screening
processes. Such small libraries are easy to maintain and can
be produced by routinely used calcium chloride mediated
transformations.
Conclusions
We have for the first time, generated anti-V3 human scFvs
against clade C HIV-1. By antigen pre-selection, the phage
library served as an adequate source of V3 positive clones.
The combination of EBV transformation and selection of
immortalized lines that exhibit the desired antigen binding
characteristics with phage display technology provides a
useful strategy for specific recombinant antibody gener-
ation. Our study validated the generation of recombinant
libraries as a powerful tool for the generation of diverse
recombinant antibodies.
Methods
Study subject, blood sample collection and processing
The HIV-1 seropositive patient (# 254) enrolled for the
construction of the anti-V3 scFv phage library was
recruited after obtaining written informed consent from
the Department of Medicine, AIIMS, New Delhi. The
study was approved by the institute ethics committee.
Whole blood was collected in EDTA vaccutainers. The
plasma was separated from whole blood, aliquoted and
stored at −70°C until tested. The peripheral blood
mononuclear cells (PBMCs) were separated by phycoll
hypaque centrifugation and processed immediately for
EBV transformation.
The plasma sample of the patient # 254 was previously
tested and found to exhibit good neutralization potential
against a diverse panel of viruses (Table 1). It was also
tested for the presence of binding anti-V3 antibodies
and the data is shown in Figure 1.
Screening of the patient plasma (#254) for cross reactive
neutralizing antibodies
The neutralization efficiency of the plasma #254was
tested against a standard panel of pseudoviruses of clades
A, B and C obtained from the NIH AIDS Research and
Reference Reagent Program, by TZM-bl assay [40]. Thestandard panel of pseudoviruses has been categorized
from tier 1 to tier 3, based on the decreasing order of sus-
ceptibility to neutralization by the known monoclonal
antibodies [41]. The neutralization assay was carried out
in 96-well tissue culture plates. Briefly, 50 μl of the heat
inactivated plasma/purified scFv, at different dilutions in
duplicate, was added to 200 TCID 50 of the virus and
incubated for 1 h. A cell control well containing culture
media only and a virus control well containing both the
culture media and the virus were tested in parallel. The rest
of the procedure is the same as described for calculating
TCID 50. The scFv (HepB), an scFv against the Hepatitis B
surface antigen [42] and 1418, a human antibody to parvo-
virus B19 protein, were used as negative controls. For all
dilutions of test plasma, the percent neutralization was
calculated based on the relative luminescence units (RLU)
in the presence of plasma divided by the virus control. The
cell control value was subtracted from the plasma RLU
value as the background cutoff. The 50% neutralization
titer (ID50 titer) was determined for the plasma sam-
ple #254 against each virus by plotting percentage
neutralization against the dilution of the plasma tested.
A non-linear regression straight line was drawn by the
method of least squares, and the reciprocal ID50 titers
were extrapolated. The experiments were performed in
duplicate and repeated at least twice and the mean ID50
titers were calculated.
Quantitation of the levels of anti-V3 Abs by Peptide ELISA
The anti-V3 Antibody content in the HIV-1 seropositive
plasma sample #254 and in the supernatants of the EBV
transformed PBMCs in culture at different stages was
determined using V3 peptide ELISA. Thirty five mer
peptides of V3C (CTRPNNNTRKSIRIGPGQTFYATGDI
IGDIRQAHC) and V3B (CTRPNNNTRKSIHIGPGRAFY
TTGEIIGDIRQAHC) were synthesised (Sigma Aldrich,
USA), based on the consensus V3 sequences. The V3 pep-
tides (1 μg/ml) were coated onto 96 well Nunc-Immuno
plates (Nunc: Cat# 439454) using antigen coating buffer
(150 mM Na2CO3, 350 mM NaHCO3, 30 mM NaN3, pH
9.6) at 4°C overnight. Plates were washed using phosphate
buffered saline with 0.1% Tween-20 (0.1% PBST) thrice
using a plate washer. Plates were then blocked with 100
μl of 15% fetal calf serum and incubated at 37°C for 1.5 h.
Following blocking and washing, heat inactivated plasma
(100 μl, dilution range=300-100000) or 100 μl of super-
natants from EBV transformed PBMC cultures was
added to each well and incubated for 1hour at 37°C.
After 3 washings with PBST (0.1%), the bound V3
specific antibodies were detected by addition of 100 μl of
alkaline-phosphatase conjugated anti-human IgG Fc
(1:2000 in PBST). Immune complexes were revealed
with AP-Substrate in DAE buffer and the colorimetric
reaction was stopped by the addition of 6N NaOH. The
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calculated for the plasma sample against each of the
peptide by plotting the absorbance at 405 nm against the
dilutions of the plasma sample tested. A non-linear
regression straight line was drawn by the method of
Least squares and the ID50 titers were extrapolated.
Epstein –Barr Virus (EBV) induced transformation of
PBMCs
B95 cell line comprises of EBV transformed human lympho-
blastoid cells which secrete EBV in the supernatant. EBV
transforms human B cells [43]. We obtained the B95 cell
line from American Type Cell Culture (Cat. No. VR-1492).
B95 cells were grown in T-75 tissue culture flasks, at
100,000 cells/ml at 37°C, 5% CO2, in complete RPMI media.
After 10 days, the viral supernatant was centrifuged at
300 × g and filtered with 0.45 μm filters. Peripheral blood
mononuclear cells (PBMC) (100,000 cells/well) from the
patient #254 were EBV transformed by mixing with 100
μl of the viral supernatant in a 96-well plate and cultured
with a polyclonal B cell activator, CpG (2 μg/ml), which
enhanced EBV infection and B cell transformation [44]
and CsA (0.5 μg/ml). The plate was incubated at 37°C in
a 5% CO2 incubator overnight. Next day, cells were fed
with 100 μl of complete medium containing CsA and
CpG. Cultures were fed twice per week and half of the
culture supernatant was replaced with fresh complete
media, 200 μl/well (no CsA and CpG).
Screening of B-lymphocytes producing anti-V3 antibodies
After two weeks of culturing the B cells in the 96 well
plate, we screened for the presence of V3 antibodies by
V3 peptide binding ELISA as described above. The positive
B cell clones were further expanded to 24 well plates and
screened in the 3rd and 4th week; V3 positive clones were
transferred to a six well plate, pooled and further expanded
to the T-25 flask (Table 2).
Construction of Human anti-V3 scFv phage library
Total RNA from the V3 specific antibody producing B
cells (from flask stage) was isolated by Trizol reagent
(Sigma, USA) and then reverse transcribed to cDNA, using
the reverse aid MMuLV reverse transcriptase (Fermentas,
USA). A total of 200 ng of RNA was reverse transcribed in
a reaction volume of 50 μl containing, 10ng of random
hexamer, 20μM oligo-dT, 1.5 μl of RNase inhibitor
(40U/μl), all dissolved in 1X RT buffer. The RNA was
heated to 65°C for 5 min and then immediately chilled
on ice for at least five minutes. Following the addition of
the reaction mixture, the tube was incubated at 42°C for
60 min, at 70°C for 5 min and quickly chilled on ice and
stored in −20°C. Heavy chain variable region genes were
amplified using a total of 24 combinations (6 forward
primers and 4 reverse primers representing all humanimmunoglobulin subfamilies) and for light chain kappa,
a total of 30 combinations were used (6 forward primers
and 5 reverse primers) as described previously [15]. A
total of 54 independent reactions were performed to
generate the variable regions of heavy and light chains.
The heavy chain 50 primers included a SfiI site and the
light chain 30primer included a NotI site. Light chain 50
primer included part of the linker region (Gly4Ser)3 and
this was compatible with the heavy chain 30 primer. Each
variable heavy region was amplified using Hot start Taq
DNA polymerase (Fermentas) in a PCR reaction of 50 μl
containing 2.5 μl cDNA, primers 1 μl (10 pmole each)
both forward and reverse. PCR reaction was performed
for 34 cycles (94°C for 3 min initial denaturation, 94°C
for 1 min, annealing at 63°C for 1 min, extension at 72°C
for 2 min) using eppendorf Master Cycler. Light chain
variable region were amplified with the similar protocol
except the annealing temperature used was 57°C. Each
variable region gene was purified from the agarose gel
using gel extraction kit (Qiagen, Germany). An equimolar
mixture of pooled heavy and light chain DNA was used in
the second round assembly PCR. The assembly PCR
reaction was cycled 20 times (94°C for 1 min, 94°C for 45
sec, 62°C for 50 sec, 72°C for 2 min) the assembly reaction
was performed using Pfu DNA polymerase and without
primers. Full length scFvs were amplified using a pull
through PCR reaction using Taq DNA polymerase and
the following primers PTfw 50 CCT TTC TAT GCG
GCC CAG CCG GCC ATG GCC 30 and PTrv 50 CAG
TCA TTC TCG ACT TGC GGC CGC ACG 30 (94°C
for 1 min, annealing at 62°C for 1min, extension at 72°C
for 1 min and final extension at 72°C for 5 min). The
scFvs were agarose gel purified using gel extraction kit
(Qiagen, Germany).
Cloning of anti-V3 scFv into pCANTAB -5E vector
The scFv DNA fragments and pCANTAB-5E vector
were digested with NotI /SfiI (New England Biolabs, USA)
respectively. The digested scFv DNA fragments and
pCANTAB-5E vector were gel purified using gel extraction
kit (Qiagen, Germany). The scFv DNA was ligated into vec-
tor at a 3:1 molar ratio using T4 DNA ligase (New England
Biolabs, USA). The ligated DNA was transformed into
chemically competent cells of E.coli TG1 and placed on ice
for 1h followed by heat shock treatment for 90 seconds and
chilled on ice for 5 min. Next, 800 μl of 2XYT media was
added and incubated in a rotating shaker at 200 rpm for 40
min. The transformed cells were plated on to 2XYT
medium agar plates containing ampicillin (50 mg/ml) and
2% glucose, and incubated overnight at 37°C. The following
day, colonies were scraped into 1ml of 2XYT medium with
20% glycerol and stored at −70°C. Sequence of the
assembled scFv was confirmed by an automated ABI prism
sequencer using gene specific primers.
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The phage were rescued by infection with helper phage
(M13-KO7), followed by precipitation with PEG/NaCl,
resuspension in PBS and titration for the determination
of phage concentration. The phage were then subjected
to a single round of enrichment by bio-panning.
The panning procedure was carried out in Immuno 96
microwell plates. Plates were coated with 100 μl of V3
peptide 1 μg/ml in 0.1 M NaHCO3 (pH 8.6) overnight at
4°C. A phage library of 1012 phage was incubated for 1h
in milk coated wells to remove the non-specific binders.
After one hour, unbound phage were transferred to the
peptide coated wells for 30 min at RT. The unbound
phage was eliminated by washing 10–15 times with PBS
containing 0.1% Tween 20. The bound phage was eluted
with 0.2 M glycine pH 2.2 for 10 min at RT. The eluted
phage were neutralized with 1M Tris HCl pH 9.2 and
immediately infected onto TG1 (OD 0 .4 to .5) for 30
min at 37°C and for 30 min with shaking at 37°C. Cells
were spun down and plated on 2XTY agar containing
ampicillin (50 mg/ml) and 2% glucose. Individual
colonies were picked and grown in 96 well sterile culture
plates (Corning) and a glycerol stock was made and
stored at −70°C.
Phage Rescue (24 well plate)
Individual colonies were grown in 1ml 2XYT broth con-
taining ampicillin and 2% glucose overnight with shaking
at 37°C at 160 rpm. A small inoculum was transferred to
1ml 2XYT broth containing ampicillin (50 mg/ml) and
2% glucose at 37°C with shaking at 200 rpm till the OD
reached 0.4 to 0.5. Helper phage were added and the
plate was incubated at 37°C without shaking and then
for 30 min with shaking at 180 rpm at 37°C. The cells
were spun down at 1500 × g, the supernatant was
discarded and pellet was washed with 2XYT broth. The
pellet was then resuspended in 2XYT broth containing
ampicillin (50 mg/ml) and kanamycin (100 mg/ml)
(no glucose) with shaking at160 rpm at 30°C for 16–18 h.
It was then centrifuged at 6000 × g and the supernatant
was collected and stored at 4°C and an aliquot was tested
in the phage ELISA.
Phage ELISA
The ELISA plates were coated with 100 μl of V3 peptide
(1 μg/ml) in 0.1 M NaHCO3 (pH 8.6) and incubated
overnight at 4°C. The plates were washed once with 1X
PBS and blocked with 4% non-fat milk (Titan Biotech,
India) for 2 h at 37°C. The plates were then washed
three times with 1X PBS. Phage supernatant (100 μl)
was added to each well and incubated for 1h at RT.
Phage supernatant was discarded and the plates were
washed four times with PBST(0.1%). 100 μl of anti M13
antibody (diluted 1:2000) was added (Sigma) and incubatedfor 1h at RT. The plates were washed four times with PBST
(0.1%). 100 μl of anti rabbit HRP (Jackson) diluted 1:3000
were added and incubated at RT for 1h. The plates were
then washed four times with PBST (0.1%). 100 μl of TMB
substrate was added, and the reaction was stopped by
adding 8N H2SO4. Absorbance was measured at 450nm.
PEG precipitation of phage (pure phage preparation)
Individual bacterial colonies were grown in 5ml 2XYT
medium containing ampicillin (50 mg/ml) and 2% glucose
with shaking at 200 rpm at 37°C till the O.D reached 0.4
to 0.5. Next, 1 μl of KO7 helper phage (1018) was added
and incubated at 37°C for 30 min without shaking,
followed by 30 min shaking at 200 rpm. The cells were
centrifuged at 2500 × g for 10 min, supernatant was
discarded and the pellet was washed again with 2XYT
broth. The pellet was resuspended in 50ml 2XYT
broth containing Ampicillin (50 mg/ml) and Kanamycin
(100 mg/ml) (no glucose) at 30°C with shaking at 160 rpm
for 12–16 h. It was then centrifuged at 10000 × g for 20
min at 4°C. The supernatant was transferred to glass
bottles and ¼ volume of PEG/NaCl was added and kept
on ice for 4 to 6 h followed by centrifugation at 20000
× g for 20 min at 4°C. The supernatant was discarded
and the pellet was dissolved in sterile and autoclaved
1X PBS and stored at 4°C. The transformation unit
(TU) was calculated.
DNA sequencing and sequence analysis
Twenty nine scFvs clones were randomly selected from
the unselected library and sequenced by Macrogen
(South Korea). The sequences were analysed using im-
munoglobulin BLAST [45] and V BASE software [46].
DNA fingerprinting of antibody fragments
The diversity of the scFv repertoire was analysed by
comparing the restriction digestion pattern of scFvs. Ten
clones were randomly selected from the primary phage
library and the plasmid was isolated. The scFv sequences
were amplified using primers PTfw 50 CCT TTC TAT
GCG GCC CAG CCG GCC ATG GCC 30 and PTrv 50
CAG TCA TTC TCG ACT TGC GGC CGC ACG 30
(94°C for 1 min, annealing at 62°C for 1min, extension
at 72°C for 1 min and final extension at 72°C for 5 min).
The amplified PCR products were digested with a frequent
cutter restriction enzyme BstN1 (NEB) and analysed on 2%
agarose gel.
Soluble scFv expression
Clones showing positivity/binding in phage ELISA were
selected for soluble scFv expression. These were than
transformed into HB2151 using calcium chloride mediated
transformation for soluble scFv expression. The HB2151
cells carrying pCANTA-5E plasmid were grown in 10 ml
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The next day, 1/100th volume of the overnight culture was
inoculated in 1 litre of 2XTY medium and grown at 37°C
with shaking at 240 rpm till the OD reached 0.6 and then
the culture was induced by 1 mM IPTG for 6 to 8 h at
24°C [33]. Cells were harvested and different fractions were
prepared. scFvs were purified from the periplasmic frac-
tion. Briefly, the cells were harvested by centrifugation at
4000 × g for 15 min at 4°C. The supernatant was discarded
and pellet was resuspended in 30 mM Tris-Cl. 20% su-
crose, pH 8.0 at 80 ml/ gram wet weight. The cells were
placed on ice for 20 min and 500 mM EDTA was added to
a final concentration of 1 mM EDTA. The cells were spun
down at 8000 × g for 15 min at 4°C. The pellet was resus-
pended in 5 mM MgSO4 and the cells were placed on
ice for 10 min with slowly stirring, pelleted down at
8000 × g for 15 min at 4°C and the supernatant col-
lected for purification.
Purification of E-tagged scFv
Purification of E-tagged scFv was carried out using the
Recombinant Phage Antibody System (RPAS) Purification
Module (Amersham Biosciences) as per the manufacturer’s
instructions. The periplasmic extract was filtered through a
0.45 μm filter to remove any remaining cell debris. The
Anti-E Tag column was regenerated by washing the column
with 15ml of elution buffer (0.1 M glycine, pH 3.0) and was
then equilibrated with 25 ml binding buffer (0.02 M
phosphate buffer, 0.005% NaN3, pH 7.0). The E-tagged scFv
in the periplasmic extract was then allowed to bind to the
column by passing the extract through the column. The
unbound excess E. coli proteins were removed from the
column by washing it with 25 ml binding Buffer. The flow
rate at each step was maintained at 5 ml/min through the
column. Finally, the bound scFv was eluted by 15ml elution
buffer. Several fractions of the eluted scFv (900 μl each)
were collected in tubes containing 100 μl neutralization
buffer (1 M Tris, 0.05% NaN3, pH 8.2). The amount of pro-
tein in each fraction was estimated using BCA method and
the fractions containing considerable amount of scFv were
pooled together and concentrated.
Soluble ELISA
Soluble ELISA was performed, as described in the phage
ELISA. Hundred microliter of soluble scFv periplasmic
extract/purified scFv was added and incubated at room
temperature for 1h. ELISA plates were washed three
times with 0.1% PBST and incubated with 1:1000 dilution
of primary antibody in 2% MPBS. The plates were washed
three times with 0.1% PBST and incubated with 1:2000
diluted anti rabbit HRP conjugated secondary antibody in
2% MPBS. The ELISA plates were washed again as
described above. 100 μl of TMP substrate was added and
incubated at RT till the colour developed. Reaction wasstopped by adding 8NH2SO4. Absorbance was read at
450 nm.
SDS-PAGE and Western blot
SDS-PAGE was done as described [33]. Proteins were
separated on a 12% running gel and 5% stacking gel and
visualized by Coomassie Brilliant Blue (CBB) staining.
For Western blotting, gel was blotted onto nitrocellulose
membrane using electroblotting, (100 V for 1h) and
probed with primary antibody. Anti-rabbit HRP was
used as secondary antibody and colour was developed
with DAB as the substrate.
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